Bicara Therapeutics (NASDAQ:BCAX) Earns Outperform Rating from Wedbush

Wedbush restated their outperform rating on shares of Bicara Therapeutics (NASDAQ:BCAX) in a research report sent to investors on Wednesday,Benzinga reports. They currently have a $31.00 price objective on the stock.

Several other research analysts have also recently weighed in on BCAX. Rodman & Renshaw began coverage on Bicara Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating and a $48.00 price objective on the stock. HC Wainwright raised their price target on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Finally, RODMAN&RENSHAW raised shares of Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $41.20.

Bicara Therapeutics Trading Up 1.5 %

Bicara Therapeutics stock opened at $13.22 on Wednesday. Bicara Therapeutics has a twelve month low of $11.10 and a twelve month high of $28.09. The firm has a 50-day moving average of $15.27.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). As a group, equities analysts forecast that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bicara Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of BCAX. Spire Wealth Management acquired a new stake in Bicara Therapeutics in the fourth quarter valued at about $31,000. SG Americas Securities LLC bought a new position in shares of Bicara Therapeutics in the fourth quarter worth about $147,000. Corebridge Financial Inc. acquired a new stake in shares of Bicara Therapeutics in the 4th quarter valued at approximately $167,000. Cinctive Capital Management LP bought a new stake in shares of Bicara Therapeutics during the 3rd quarter valued at approximately $229,000. Finally, Barclays PLC acquired a new position in Bicara Therapeutics during the 3rd quarter worth approximately $255,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.